Icosapent ethyl is a Small Molecule owned by Mochida Pharmaceutical, and is involved in 8 clinical trials, of which 6 were completed, and 2 are ongoing.

Ethyl icosapentate (EPA-E) is a Diglyceride Acyltransferase (DGAT) Inhibitor. It is a platelet aggregation inhibitor, antagonize or impair any mechanism leading to blood platelet aggregation. MND-21 has anti-inflammatory and cardiovascular benefits due to an abundance of polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA). EPA ethyl ester (EPA-EE) is a stabilized ethyl ester form. It competitively inhibits the metabolism of arachidonic acid by cyclooxygenase enzymes, suggesting that EPA-EE may also directly modulate the actions of enzymes involved in fatty acid metabolism.

The revenue for Icosapent ethyl is expected to reach a total of $500m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Icosapent ethyl NPV Report.

Icosapent ethyl is currently owned by Mochida Pharmaceutical.

Icosapent ethyl Overview

Ethyl icosapentate (Epadel S, Epadel EM) is a highly purified omega-3 fatty acid that acts as an anti hypertriglyceridemic agent. It is formulated as soft gelatin capsules for oral route of administration. It is indicated for the improvement of ulcer, pain and cooling sensation accompanying arteriosclerosis obliterans and Hyperlipidemia.

Ethyl icosapentate is under development for the treatment of hypertriglyceridemia in Japan and China. It was under development for the treatment of Behcet's disease and non-alcoholic steatohepatitis (NASH).

Mochida Pharmaceutical Overview

Mochida Pharmaceutical (Mochida) develops, manufactures, and markets pharmaceutical and healthcare products including generics, specialty pharmaceuticals, and biosimilar products. The company’s products are used for the treatment of arteriosclerosis obliterans, hyperlipidemia, pulmonary arterial hypertension, endometriosis, adenomyosis, thrombosis, acute pancreatitis, depression and depressive symptoms, chronic pain, cancer, chronic constipation, ulcerative colitis, gout and hyperuricemia, anticoagulant, antimycotic, and others. Its products under development are intended for the treatment of ulcerative colitis, insomnia, hyperlipidemia, articular cartilage lesion, and others. The company also offers contract manufacturing of pharmaceuticals. It operates state of art manufacturing facilities in Japan involved in technology transfers and the development of new drugs. Mochida is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY110,179 million for the fiscal year ended March 2022 (FY2022), an increase of 7% over FY2021. In FY2022, the company’s operating margin was 12.4%, compared to an operating margin of 11.4% in FY2021. In FY2022, the company recorded a net margin of 9.6%, compared to a net margin of 8.3% in FY2021. The company reported revenues of JPY25,508 million for the second quarter ended September 2022, a decrease of 7.9% over the previous quarter.

Quick View – Icosapent ethyl

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Icosapent ethyl
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.